Jay K. Wathen, Ph.D.
Affiliations: | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Statistics, Biostatistics BiologyGoogle:
"Jay Wathen"Parents
Sign in to add mentor| Peter F. Thall | grad student | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston | |
| (Bayesian doubly optimal group sequential designs for randomized clinical trials.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wathen JK, Thall PF. (2017) A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clinical Trials (London, England). 14: 432-440 |
| Schuetze SM, Wathen JK, Lucas DR, et al. (2015) SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer |
| Thall P, Fox P, Wathen J. (2015) Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1621-8 |
| Morgan CC, Huyck S, Jenkins M, et al. (2014) Adaptive Design: Results of 2012 Survey on Perception and Use Therapeutic Innovation and Regulatory Science. 48: 473-481 |
| Lionberger JM, Dorcy KS, Dean C, et al. (2011) Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML Blood. 118: 1552-1552 |
| Chugh R, Wathen JK, Patel SR, et al. (2010) Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4884-91 |
| Wathen JK, Thall PF. (2008) Bayesian adaptive model selection for optimizing group sequential clinical trials. Statistics in Medicine. 27: 5586-604 |
| Thall PF, Wathen JK. (2008) Bayesian designs to account for patient heterogeneity in phase II clinical trials. Current Opinion in Oncology. 20: 407-11 |
| Wathen JK, Thall PF, Cook JD, et al. (2008) Accounting for patient heterogeneity in phase II clinical trials. Statistics in Medicine. 27: 2802-15 |
| Maki RG, Wathen JK, Patel SR, et al. (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2755-63 |